Skip to search boxSkip to navigationSkip to main content

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

  • Amy Baldwin
    ,
  • Dorre A. Grueneberg
    ,
  • Karin Hellner
    ,
  • Jacqueline Sawyer
    ,
  • Miranda Grace
    ,
  • Wenliang Li
*Corresponding author for this work
  • Harvard University
    ,
  • St. George's University
    ,
  • Augusta Pharmaceuticals Inc.
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Cervical carcinomas are initiated through a series of well-defined stages that rely on the expression of human papillomavirus (HPV) oncogenes. A panel of 100 small hairpin RNAs that target essential kinases in many tumor types was used to study the stepwise appearance of kinase requirements during cervical tumor development. Twenty-six kinases were commonly required in three cell lines derived from frank carcinomas, and each kinase requirement was traced to the specific stage in which the requirement emerged. Six kinases became required following HPV-induced immortalization, and the requirement for two kinases, SGK2 and PAK3, was mapped to the inactivation of p53 in primary human epithelial cells. Loss of the p53 tumor suppressor in other primary epithelial cells also induced dependence on SGK2 and PAK3. Hence, SGK2 and PAK3 provide important cellular functions following p53 inactivation, fulfilling the classical definition of synthetic lethality; loss of p53, SGK2, or PAK3 alone has little effect on cell viability, whereas loss of p53 together with either SGK2 or PAK3 loss leads to cell death. Whereas tumor suppressor gene mutations are not directly druggable, other proteins or pathways that become obligatory to cell viability following tumor suppressor loss provide theoretical targets for tumor suppressor-specific drug discovery efforts. The kinases SGK2 and PAK3 may thus represent such targets for p53-specific drug development.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 12463-12468 (6 pages)

Journal (Volume, Issue Number)

Proceedings of the National Academy of Sciences of the United States of America (Volume 107, Issue 28)

Publication milestones

  • Published - 07/13/2010

Publication status

Published - 07/13/2010

ISSN

0027-8424

Publication IDs

  • Scopus: 77955464738
  • PubMed: 20616055

Publication metrics

Metrics

SciVal
FWCI
0.94
SciVal
Author count
8
SciVal
citations
44
SciVal
Paper percentile
89
Scopus
citations
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
53
Captures
88